Trial Profile
Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Oct 2022 Status changed to active, no longer recruiting.
- 18 Dec 2021 Status changed from recruiting to suspended.
- 08 Sep 2021 Planned End Date changed from 1 Feb 2022 to 1 Dec 2024.